Fig 1: Stromal overexpression of the selected proteins correlates with pathological feature and prognosis in patients with PDAC.a Statistical analysis of protein expression in view of clinical and pathological features of PDAC patients. b Expression of SFN is associated with a poor differentiation. c Kaplan–Meier curves and log-rank analysis of overall survival (OS) (left panels) and disease-free survival (DFS) (right panels) according to the expression of SFN or ITGB6 in the stroma of resected PDAC. Staining was scored as negative (0), mild (1), moderate (2) or strong (3).
Fig 2: Validation of mRNA profiles at a protein level.a mRNA analysis of the selected genes demonstrated a significant increase in the expression of KRT19, SFN, ITGB6, ADAMTS12, TNFSF9 and CXCL3 in the stroma of PDAC as compared to the adjacent NT fibrous tissue. p Value was determined by using a two-tailed Student’s t test. b Immunohistological analysis of KRT19, SFN, ITGB6, ADAMTS12, TNFSF9 and CXCL3 protein expression in the stroma (T) and the surrounding NT fibrous tissue (NT) of an independent set of 80 patients with resected PDAC. Staining was scored as described in the “Materials and methods” section: negative (0), mild (1), moderate (2), or strong (3). The expression of SFN, ADAMTS12 and CXCL3 was significantly increased in the stroma of PDAC. c Representative strong immunostaining in stroma of PDAC of SFN, ADAMTS12 and CXCL3.
Supplier Page from CUSABIO Technology LLC for Human 14-3-3 protein sigma(SFN) ELISA Kit